Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy (vol 10, e004600, 2022)

被引：0
|
作者：
Simister, P. C.
Border, E. C.
Vieira, J. F.
机构：
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷 / 09期
关键词：
D O I：
10.1136/jitc-2022-004600corr1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：1
相关论文
共 11 条
  • [1] Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy
    Simister, Philip C.
    Border, Ellen C.
    Vieira, Joao F.
    Pumphrey, Nicholas J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
  • [2] Selection of affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10
    Border, Ellen
    Sanderson, Joseph P.
    Weissensteiner, Thomas
    Hyland, Natalie
    Holdich, Tom
    Brophy, Francine
    Amado, Rafael
    Gerry, Andrew
    Pumphrey, Nicholas
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate
    Border, Ellen C.
    Sanderson, Joseph P.
    Weissensteiner, Thomas
    Gerry, Andrew B.
    Pumphrey, Nicholas J.
    ONCOIMMUNOLOGY, 2019, 8 (02):
  • [4] Engineering a Dual Specificity γδ T-Cell Receptor for Cancer Immunotherapy
    Davies, David M.
    Pugliese, Giuseppe
    Pereira, Ana C. Parente
    Whilding, Lynsey M.
    Larcombe-Young, Daniel
    Maher, John
    BIOLOGY-BASEL, 2024, 13 (03):
  • [5] Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy (vol 10, e003960corr1, 2022)
    Jiang, X.
    Wang, J.
    Zheng, X.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (09)
  • [6] Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells (vol 10, e004479corr1, 2022)
    Martin-Otal, C.
    Lasarte-Cia, A.
    Serrano, D.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (09)
  • [7] Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy (vol 10, e004790, 2022)
    Xiong, C.
    Huang, L.
    Kou, H.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (11)
  • [8] Clinical chimeric antigen receptor T-cell therapy: a new and promising treatment modality for glioblastoma (vol 10, e1050, 2021)
    Brown, Michael P.
    Ebert, Lisa M.
    Gargett, Tessa
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (08)
  • [9] Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells (vol 10, e004693corr1, 2022)
    Maddineni, S.
    Silberstein, J. L.
    Sunwoo, J. B.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (09)
  • [10] CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy (vol 10, e004022, 2022)
    Xiao, M.
    Xie, L.
    Cao, G.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
12